Cav2 - caveolin 2 Gene

Species: Mus musculus

Gene Type: protein coding

Gene ID: 12390

Summary

This gene belongs to the caveolin family whose members encode the major protein components of caveolae, which are invaginations of plasma membrane. This gene is located adjacent to caveolin-1 and the proteins coexpressed by the two genes localize together in caveolae, where they form hetero-oligomers. The encoded protein may be involved in diverse cellular functions including proliferation, differentiation, endocytosis and trafficking. Alternative splicing of this gene results in transcript variants encoding different isoforms. [provided by RefSeq, Apr 2013]

Cav2 Products (2)

mRNA	Protein	Name
NM_001277756.1	NP_001264685.1	caveolin-2 isoform 2
NM_016900.4	NP_058596.1	caveolin-2 isoform 1

Gene Ontology

Molecular Function
Biological Process
Cellular Component

Molecular Function GO Annotation	Evidence	References	Source
enables molecular adaptor activity	IDA IDA: Inferred from direct assay	12091389	MGI
enables protein binding	IPI IPI: Inferred from physical interaction	17715130	MGI
enables protein heterodimerization activity	IPI IPI: Inferred from physical interaction	9361015	MGI
enables protein kinase binding	IDA IDA: Inferred from direct assay	12091389	MGI
enables protein kinase binding	IPI IPI: Inferred from physical interaction	12091389	MGI
enables protein-macromolecule adaptor activity	IDA IDA: Inferred from direct assay	12091389	MGI
enables scaffold protein binding	IPI IPI: Inferred from physical interaction	12091389	MGI

Biological Process GO Annotation	Evidence	References	Source
acts upstream of or within basement membrane organization	IMP IMP: Inferred from mutant phenotype	11884617	MGI
acts upstream of cell population proliferation	IMP IMP: Inferred from mutant phenotype	17200204	MGI
acts upstream of or within endoplasmic reticulum organization	IMP IMP: Inferred from mutant phenotype	17200204	MGI
acts upstream of endothelial cell proliferation	IGI IGI: Inferred from genetic interaction	21832243	MGI
acts upstream of endothelial cell proliferation	IMP IMP: Inferred from mutant phenotype	11884617	MGI
acts upstream of or within mitochondrion organization	IMP IMP: Inferred from mutant phenotype	17200204	MGI
acts upstream of or within negative regulation of endothelial cell proliferation	IMP IMP: Inferred from mutant phenotype	11884617	MGI
acts upstream of or within negative regulation of skeletal muscle cell proliferation	IMP IMP: Inferred from mutant phenotype	17200204	MGI
acts upstream of or within negative regulation of transforming growth factor beta receptor signaling pathway	IGI IGI: Inferred from genetic interaction	21832243	MGI
acts upstream of or within positive regulation of endothelial cell proliferation	IGI IGI: Inferred from genetic interaction	21832243	MGI
acts upstream of skeletal muscle cell proliferation	IMP IMP: Inferred from mutant phenotype	17200204	MGI
acts upstream of or within skeletal muscle fiber development	IMP IMP: Inferred from mutant phenotype	17200204	MGI
acts upstream of transforming growth factor beta receptor signaling pathway	IGI IGI: Inferred from genetic interaction	21832243	MGI

Cellular Component GO Annotation	Evidence	References	Source
located in acrosomal membrane	IDA IDA: Inferred from direct assay	19144954	MGI
located in caveola	IDA IDA: Inferred from direct assay	11884617	MGI
part of caveolar macromolecular signaling complex	IDA IDA: Inferred from direct assay	11884617	MGI
colocalizes with focal adhesion	IDA IDA: Inferred from direct assay	12091389	MGI
located in membrane	IDA IDA: Inferred from direct assay	11316799	MGI
located in plasma membrane	IDA IDA: Inferred from direct assay	11884617	MGI
part of protein-containing complex	IDA IDA: Inferred from direct assay	12091389	MGI

EXP: Inferred from Experiment IDA: Inferred from direct assay IPI: Inferred from physical interaction IMP: Inferred from mutant phenotype IGI: Inferred from genetic interaction IEP: Inferred from expression pattern

Protein Preferred Names	Protein Names
caveolin-2

Related Agents

Clinical Phase
Pre-clinical Phase

Clinical Phase

Bioactive Molecules (1)

Cat. No.	Product Name	Effect	Purity	Phase
HY-132268	Cav 2.2 blocker 2	Inhibitor	98.51%	Phase 2

Pre-clinical Phase

Bioactive Molecules (23)

Cat. No.	Product Name	Effect	Purity	Rare Diseases
HY-P1080A	ω-Agatoxin IVA TFA	Inhibitor	99.52%	Unkown
HY-P1074	SNX-482	Inhibitor	≥99.0%	Unkown
HY-119373	Cav 2.2 blocker 1	Inhibitor	98.85%	Unkown
HY-120751	TROX-1	Inhibitor	99.55%	Unkown
HY-164803	CBD3063	Modulator	99.75%	Unkown
HY-P1080	ω-Agatoxin IVA	Inhibitor	98.71%	Unkown
HY-115597	BTT-266	Antagonist	98.90%	Unkown
HY-120751A	(S)-TROX-1	Inhibitor	99.52%	Unkown
HY-115596	BTT-369	Antagonist	/	Unkown
HY-147639	Cav 2.2/3.2 blocker 1	Inhibitor	/	Unkown
HY-148866	Cavα2δ1&NET-IN-3	Inhibitor	/	Unkown
HY-169845	Calcium Channel antagonist 6	Antagonist	/	Unkown
HY-180400	PAM-2		/	Unkown
HY-181612	COX-2/CaV2.2-IN-1	Inhibitor	/	Unkown
HY-181957	KB528		/	Unkown
HY-P10898	GeX-2		/	Unkown
HY-P5813	Cd1a	Inhibitor	/	Unkown
HY-P5874	Myr-TAT-CBD3	Inhibitor	/	Unkown
HY-RS01987	CAV2 Human Pre-designed siRNA Set A	Pre-designed Set	/	Unkown
HY-N12768	Rhodojaponin VI	Inhibitor	99.78%	Unkown
HY-P3269	Calciseptine	Inhibitor	/	Unkown
HY-RS20256	Cav2 Mouse Pre-designed siRNA Set A	Pre-designed Set	/	Unkown
HY-RS26764	Cav2 Rat Pre-designed siRNA Set A	Pre-designed Set	/	Unkown

Orthologs Information

Species	Symbol	Source	ID
Homo sapiens	Cav2	NCBI	NCBI:858